Researchers
Tim R. Randolph
Summary
This invention relates generally to a simple and cost-effective method of quantitative fetal hemoglobin (HbF) measurement using non-hazardous reagents and suitable for laboratories in the developing world. A more recent approach to treating sickle cell anemia involves the drug hydroxyurea to increase expression of HbF to reduce the frequency of vaso-occlusive events. However, patients exhibit a wide range of baseline HbF levels and response to this drug. Since hydroxyurea is mildly carcinogenic, HbF levels must be monitored during treatment to determine the minimum effective dosage.
Intellectual Property Status
- U.S. patent pending